BLD Form 4: Director Tina Donikowski reports sale, retains 4,245 shares
Rhea-AI Filing Summary
TopBuild Corp. (BLD) director Tina Donikowski reported a sale of 370 shares of TopBuild common stock on 08/27/2025 at a reported price of $427.89 per share. After the sale she beneficially owned 4,245 shares. The Form 4 was signed by an attorney-in-fact on 08/29/2025. The filing indicates a routine insider disposition with no derivative transactions disclosed.
Positive
- Director retains a position with 4,245 shares beneficially owned after the sale
- Filing is specific and contains transaction details (date, price, amount), supporting transparent disclosure
Negative
- Insider sale of 370 shares could be viewed negatively by some investors despite its modest size
- No Rule 10b5-1 plan checkbox was indicated on the form, so sale was not explicitly reported as part of a prearranged plan
Insights
TL;DR: Director sold a modest number of shares; remaining beneficial holding remains meaningful but not large.
The reported sale of 370 shares at $427.89 reduces the director's stake to 4,245 shares. This is a direct sale (code S) reported on Form 4 and executed via attorney-in-fact signature. There are no derivative transactions or additional context in the filing to suggest accelerated selling or hedging activity. For most investors this is a routine insider sale rather than a company-level signal.
TL;DR: Disclosure is compliant and specific; no governance red flags in this single Form 4.
The form lists the reporter as a director and identifies the relationship and address. The filing shows proper reporting of the transaction date, price, and post-transaction ownership. Absence of a Rule 10b5-1 checkbox or plan disclosure means no affirmative defense was claimed on the form itself. Based solely on this filing, there are no governance concerns disclosed.
FAQ
What transaction did Tina Donikowski report on Form 4 for BLD?
How many TopBuild (BLD) shares does the reporting person own after the sale?
Was the Form 4 signed and who signed it?
Does the filing disclose any derivative transactions or option exercises?
Is there any indication the sale was made under a 10b5-1 plan?